Current drug therapies for benign prostatic hyperplasia involve t

Current drug therapies for benign prostatic hyperplasia involve the use of α1 receptor antagonists to remove dynamic obstructions and 5α reductase inhibitors

to remove mechanical obstructions.35 Our data show that even losartan treatment does not change the high micturition pressure levels believed to be due to BOO. Furthermore, because partial urethral ligation was not removed during our experiment, BOO is believed to have been maintained even in the losartan group. However, losartan treatment improved the voiding efficiency of obstructed bladders by prolonging the micturition interval, increasing the urine volume per void, and decreasing the development of residual urine volume. Our cystometry findings revealed significant prolongation of bladder contraction time in the losartan check details group compared to the BOO group. Based on this finding, we believe that losartan treatment causes an increase in the urine volume per void and a decrease

in residual urine volume by causing bladder contractions to be maintained in obstructed bladders. Furthermore, in in vitro studies, decreases in bladder strip contractile function in response to electrical field stimulation, muscarinic agonists, and depolarizing stimuli recovered following losartan treatment. Based on this finding, we believe that losartan treatment causes an increase in the urine volume per void and a decrease in residual urine volume that is an increase in functional bladder capacity by causing bladder contractions to be maintained in obstructed bladders. Recently, Yamada et al. reported that, as was observed Ixazomib in our study, oral treatment with the Etofibrate ARB telmisartan for 2 weeks effectively attenuated the increase in bladder weight caused by BOO, although they did not perform bladder functional or histological studies. Using a radioreceptor binding assay, they also showed that telmisartan and losartan bound to AT1s in the bladder

with similar affinity as binding to AT1s in the heart and kidney.29 This result suggests that the bladder, as well as cardiovascular tissue, is a target organ for AT1 antagonists. Our preliminary data and previous studies have shown that ARB prevents bladder hypertrophy, fibrosis, and dysfunction related to bladder obstruction. These findings suggest that bladder AT1s that are exposed to outlet obstruction are activated, and that this activation might be associated with the pathophysiology of bladder remodeling and dysfunction. Such bladder-directed therapy may have an important role in future therapeutic strategies for obstructed bladder, although more detailed studies of dose-response or of treatment time-dependent effects and the underlying molecular mechanism are needed. There are no financial or commercial interests concerned for the authors of the present paper. “
“Objectives: To evaluate the efficacy of clean intermittent catheterization for urinary incontinence in myelodysplastic children.

Comments are closed.